A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors

NCT05746897 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer
Melanoma
Triple Negative Breast Cancer
Colorectal Cancer

Interventions

DRUG: NM1F Injection
DRUG: Pembrolizumab injection

Sponsor

Hefei TG ImmunoPharma Co., Ltd.